New Obesity Drug Lorcaserin Passes Major Safety Tests

New Obesity Drug Lorcaserin Passes Major Safety Tests

The new obesity drug lorcaserin is in Phase 3 (final stage) trials, which are double-blind, randomized, drug trials with 3,200 patients in 100 centers in the United States. Echocardiograms were done to make sure that the new drug had no adverse effects on heart valves and so far it looks safe. Locaserin is the first in a new class of obesity drugs that target the 5-HT2C serotonin receptor, located in the hypothalamus, which regulates food intake and metabolism. The results from the Phase 2 studies showed that lorcaserin produced highly statistically significant, progressive weight loss over a 12-weeks. Lorcaserin was well tolerated at all doses in the Phase 2 drug trials and had no apparent effects on the heart valves or on the pulmonary artery pressure.http://healthblaster.com/?p=42

About the Author

A person with a keen interest in medical science.